
Dr. Coleman on Rationale for Using Veliparib and Chemotherapy in Ovarian Cancer
Robert L. Coleman, MD, FACOG, FACS, discusses what makes veliparib a unique agent in high-grade serous ovarian cancer.
Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses what makes veliparib a unique agent in high-grade serous ovarian cancer.
PARP inhibitors have been evaluated in ovarian cancer ever since preclinical models demonstrated their efficacy in BRCA1/2-mutated tumors, says Coleman. These agents have catalytic engagement of PARP and can trap the PARP enzyme onto DNA.
According to Coleman, veliparib is unique because it appears to be a weak PARP trapper which allows it to be given in combination with full-dose, cytotoxic chemotherapy.



































